Deficiency of ADAMTS13 plays a critical role in platelet accumulation in PA-ILI, suggesting that ADAMTS13 could be a potential therapeutic target for this condition.

A recombinant replacement for the ADAMTS13 protein (Adzynma) missing in congenital thrombotic thrombocytopenic purpura (TTP) restored levels and reduced acute TTP events, according to interim ...

Her condition improved following the introduction of glucocorticoids, plasma exchange, and rituximab, with a gradual return to normal values for ADAMTS13 antigen and inhibitory antibodies.

It took decades to determine, but scientists now know that the cause is a deficient enzyme: ADAMTS13. 2 Better understanding of this enzyme could create opportunities to help patients with blood ...

TAK-755 is a recombinant version of the ADAMTS13 protein designed to replace the missing enzyme, which was given in the pivotal study as an intravenous infusion once every week or every other week.